Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale
Susanne Singer(Rostock University of Music and Theatre), Christian Simon(University of Lausanne), Monica Pinto(Jagiellonian University), Amy Fullerton(Jacksonville University), Hisham Mehanna(University Hospitals Birmingham NHS Foundation Trust), Juan Ignacio Arrarás, Joaquim Castro Silva(Instituto Português de Oncologia Francisco Gentil), Sanja Krejović-Trivić(University of Belgrade), Bente Brokstad Herlofson(Oslo University Hospital), Alexander Fabian(University Hospital Schleswig-Holstein), Noam Yarom(Sheba Medical Center), Iwona M. Tomaszewska(Jagiellonian University), Naomi Kiyota(Kobe University Hospital), Allen C. Sherman(Winthrop Rockefeller Foundation), Loreto Fernández‐González(Fundación Arturo López Pérez), Ourania Nicolatou‐Galitis(National and Kapodistrian University of Athens), Lisa Licitra(University of Milan), Dina Salem(Ain Shams University), Pierluigi Bonomo(Azienda Ospedaliero-Universitaria Careggi), Kristin Bjordal(Norwegian Cancer Society), Eva Hammerlid(Sahlgrenska University Hospital), Ingo Baumann(Heidelberg University), Judith E. Raber‐Durlacher(Academic Center for Dentistry Amsterdam), Andreas Boehm(Klinikum St. Georg), Cecilie Delphin Amdal(Oslo University Hospital), Christine Brannan(Mount Vernon Cancer Centre), Johanna Inhestern, Razvan Galalae(MedAustron), Wei‐Chu Chie(National Taiwan University), Kathy Taylor(Johannes Gutenberg University Mainz), M.A. Santos
Cited by 17
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
EORTC QLQ-C30 Scoring Manual
|Research at the University of Copenhagen (University of Copenhagen)|1995|2.4k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k